The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice

BMC Musculoskeletal Disorders

Jon Packham⁴  Karen Obrenovic¹  Shireen Shaffu⁶  Sheila Catherine O’Reilly⁵  Nicola Erb²  Tahir Hashmi³  Vijay Rao³  Tim Blake⁴ 

[1]Clinical Audit Department, Russells Hall Hospital, Dudley, West Midlands DY1 2HQ, UK

[2]Rheumatology Department, Russells Hall Hospital, Dudley West Midlands DY1 2HQ, UK

[3]Rheumatology Department, Birmingham City Hospital, Dudley Road, Birmingham, West Midlands B18 7QH, UK

[4]Rheumatology Department, Haywood Hospital, High Lane, Burslem, Staffordshire ST6 7AG, UK

[5]Rheumatology Department, Royal Derby Hospital, Uttoxeter Road, Derby DE22 3NE, UK

[6]Rheumatology Department, Leicester Royal Infirmary, Infirmary Square, Leicester LE1 5WW, UK

关键词: Biologic therapies;    Commissioning;    Rheumatoid arthritis;   

Others  :  1122155
DOI  :  10.1186/1471-2474-15-290

 received in 2014-03-24, accepted in 2014-08-27,  发布年份 2014

【 摘 要 】

Background

Biologic drugs are expensive treatments used in rheumatoid arthritis (RA). Switching among them is common practice in patients who have had an inadequate response or intolerable adverse events. The National Institute of Health and Clinical Excellence (NICE) UK, which aims to curtail postcode prescribing, has provided guidance on the sequential prescription of these drugs. This study sought to evaluate the extent to which rheumatology centres across the Midlands were complying with NICE guidance on the switching of biologic drugs in RA, as well as analyse the various prescribing patterns of these drugs.

Methods

Data was collected via a web-based tool on RA patients who had undergone at least one switch of a biologic drug during 2011. The standards specified in NICE technology appraisals (TA130, TA186, TA195, TA198, and TA225) were used to assess compliance with NICE guidance. Descriptive statistical analysis was performed.

Results

There were 335 biologic drug switches in 317 patients. The most common reason given for switching to a drug was NICE guidelines (242, 72.2%), followed by Physician's choice (122, 33.4%). Lack of effect was the most common reason for discontinuing a drug (224, 67%). For patients on Rituximab, Methotrexate was used in 133 switches (76.9% of the time). Overall NICE compliance for all units was 65% (range 50 to 100%), with anti-TNFα to anti-TNFα switches for inefficacy making up the majority of non-compliant switches.

Conclusion

This study draws attention to the enigma and disparity of commissioning and prescribing of biologic drugs in RA. Currently the evidence would not support switching of a biologic drug for non-clinical purposes such as economic pressures. Flexibility in prescribing should be encouraged: biologic therapy should be individualised based on the mode of action and likely tolerability of these drugs. Further work should focus on the evidence for using particular sequences of biologic drugs.

【 授权许可】

   
2014 Blake et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 79. Rheumatoid arthritis: The Management of Rheumatoid Arthritis in Adults http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf webcite
• [2]Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, Combe B, Cutolo M, de Wit M, Dougados M, Emery P, Gibofsky A, Gomez-Reino JJ, Haraoui B, Kalden J, Keystone EC, Kvien T, McInnes I, Martin-Mola E, Montecucco C, Schoels M, van der Heijde D, T. T. Expert Comm: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010, 69:631-637.
• [3]Edwards JCW, Leandro MJ: B lymphocyte depletion therapy with rituximab in rheumatoid arthritis. Rheum Dis Clin North Am 2004, 30:393.
• [4]Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
• [5]Maini RN, Taylor PC, Pavelka K, Emery P, Szechinski J, Balint G, Broll J, Grp CS: Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). Arthritis Rheum 2003, 48:S652-S652.
• [6]Kiely PDW, Brown AK, Edwards CJ, O’Reilly DT, Ostor AJK, Quinn M, Taggart A, Taylor PC, Wakefield RJ, Conaghan PG: Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology 2009, 48:765-772.
• [7]Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester G-R, Cravets MW, Hessey EW, Shaw T, Totoritis MC, Reflex Trial Group: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
• [8]Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516-1523.
• [9]Genovese MC: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition (vol 353, pg 1114, 2005). N Engl J Med 2005, 353:2311-2311.
• [10]Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Ghogomu ET, Tugwell P: Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009. Issue 4. Art. No.: CD007848. doi:10.1002/14651858.CD007848.pub2
• [11]Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
• [12]Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Mola EM, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, Tempo Study Investigators: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
• [13]NICE TA 130 http://www.nice.org.uk/nicemedia/live/11867/37914/37914.pdf webcite
• [14]NICE TA 186 http://www.nice.org.uk/nicemedia/live/12808/47544/47544.pdf webcite
• [15]NICE TA 195 http://www.nice.org.uk/nicemedia/live/13108/50413/50413.pdf webcite
• [16]NICE TA 198 http://www.nice.org.uk/nicemedia/live/13669/58202/58202.pdf webcite
• [17]NICE TA 225 http://www.nice.org.uk/nicemedia/live/13490/54929/54929.pdf webcite
• [18]Emery P, Sarzi-Puttini P, Moots RJ, Andrianakos A, Sheeran TP, Choquette D, Finckh A, Desjuzeur ML, Gemmen EK, Mpofu C, Gottenberg JE: Relative efficacy of Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis and an inadequate response to a single previous TNF inhibitor: interim results from SWITCH-RA, a global, observational, comparative effectiveness study. Rheumatology 2012, 51:130-131.
• [19]Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma J, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G, et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
• [20]Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, Dancer Study Grp: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006, 54:1390-1400.
• [21]Deighton C, Hyrich K, Ding T, Ledingham J, Lunt M, Luqmani R, Kiely P, Bukhari M, Abernethy R, Ostor A, Bosworth A, Gadsby K, McKenna F, Finney D, Dixey J: BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy (vol 49, pg 1197, 2010). Rheumatology 2010, 49:1609-1609.
• [22]Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S: Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146:797-808.